Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
SANUWAVE Health, Inc. reports company developments tied to FDA-cleared and FDA-approved directed-energy systems used in advanced wound care. The company researches, develops and commercializes non-invasive regenerative medicine technologies designed to activate biological responses for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its wound care portfolio includes the UltraMIST product line and related product candidates.
Recurring news includes quarterly and annual revenue updates, financial guidance, conference-call materials, medical-device commercialization activity and channel relationships for UltraMIST. Company updates also describe applications of its energy transfer technologies in wound healing, orthopedic and spine, aesthetic and cosmetic, and cardiac and endovascular conditions.
SANUWAVE Health, Inc. (OTCQB: SNWV) has established a non-exclusive sales and marketing agreement with Ametus to expand its wound care product portfolio in the U.S. This partnership aims to enhance SANUWAVE's market presence in underrepresented areas, leveraging Ametus' experienced sales force. Ametus specializes in advanced wound care and medical device products, covering significant portions of the western U.S. The company is known for its innovative energy-based technologies to address chronic wounds, improving healing processes and outcomes.
SANUWAVE Health, Inc. (OTCQB: SNWV) has announced a three-year exclusive distribution agreement with Kingdom Brother for its energy-based medical systems, including dermaPACE®, UltraMIST®, and WoundShield®, across several Southeast Asian countries. This region has the second highest diabetes prevalence (11.4%), presenting a significant market opportunity for wound care solutions. The agreement includes annual purchase commitments and a fixed transfer price, enhancing SANUWAVE's market presence and potential revenue growth.
SANUWAVE Health, Inc. (OTCQB: SNWV) has announced an exclusive distribution agreement with Labb Solutions for its dermaPACE® and UltraMIST® systems in Turkey and select countries in Eastern Europe and the Middle East. The first ten dermaPACE systems have already been shipped to Turkey. These energy-based medical systems aim to enhance wound care by leveraging innovative technologies. The dermaPACE system, FDA-cleared for diabetic foot ulcers, utilizes Pulsed Acoustic Cellular Expression (PACE®) technology. Meanwhile, UltraMIST offers non-contact ultrasound treatments to promote healing.
SANUWAVE Health, Inc. (OTCQB: SNWV) has signed a non-exclusive reseller agreement with DocShop Pro to market and sell its advanced wound care products, specifically the UltraMIST®, within the physician office channel. This agreement enhances SANUWAVE's commercial reach by utilizing DocShop Pro's 16-member sales team, facilitating access to innovative treatment options in podiatry. The partnership aims to leverage the average reimbursement of $417 per treatment for UltraMIST®, enhancing patient care and business growth.
SANUWAVE Health (OTCQB: SNWV) has formed a joint venture with MEDSTENT, S.A. to market its dermaPACE® System for treating chronic wounds in Mexico. This system, cleared by COFEPRIS, addresses diabetic foot ulcers, venous and arterial ulcers, and post-surgical wounds. The partnership aims to leverage MEDSTENT's expertise in the Mexican healthcare market to enhance access to this innovative treatment. The wound care market in Mexico is expected to grow at a CAGR of 6.72% over the next five years due to an aging population and increasing chronic wounds.
SANUWAVE Health, focused on advanced wound care, announced it will participate in significant medical meetings to showcase its Energy First approach with the dermaPACE® and UltraMIST® systems. Key events include DFCon20 (Oct 9-10), PRESENT e-Learning Systems (Oct 13), and The Academy of Physicians in Wound Healing Symposium (Oct 16-18). These platforms aim to educate specialists on innovative treatments for chronic wounds. The company's technologies enhance healing by combining energy transfer methods to improve patient outcomes.